Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
Repeated immunizations of goats, horses, or chimpanzees with envelope glycoprotein gp120 isolated from human immunodeficiency virus type 1 (HIV-1) resulted in type-specific neutralizing-antibody responses, which began to decay approximately 20 days following the administration of antigen. This was true repeatedly for serum samples from animals hyperimmunized with gp120s from either the HTLV-IIIB (IIIB) or the envelope-divergent HTLV-IIIRF (RF) HIV-1 isolates. Animals previously immunized with the IIIB gp120 were then inoculated with purified RF gp120. The first response in these animals was an anamnestic resurgence of neutralizing antibody to IIIB without detectable neutralizing antibody for RF. However, with later RF gp120 boosts, the IIIB neutralizing-antibody titers fell and an RF type-specific neutralizing-antibody response developed. When assessed with other HIV-1 variants, no group-specific neutralizing antibody was seen in any of the vaccination protocols evaluated. These results will pose real obstacles in the development of an effective vaccine for HIV.
Nara
P L
PL
Office of the Director, National Cancer Institute-Frederick Cancer Research Facility, Maryland 21701.
Robey
W G
WG
Pyle
S W
SW
Hatch
W C
WC
Dunlop
N M
NM
Bess
J W
JW
Kelliher
J C
JC
Arthur
L O
LO
Fischinger
P J
PJ
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D006041:Goats; D006678:HIV / Q000276:immunology*; D006736:Horses; D008562:Membrane Glycoproteins / Q000276:immunology; D009500:Neutralization Tests; D002679:Pan troglodytes; D013997:Time Factors; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins